This is a service of EIN news a digital news provider

Chronic Lymphocytic Leukemia Newsletter sign up now

  • Roche uniquely positioned to deliver long-term growth (18 Mar 2010 08:41)

    ... the treatment of malignant melanoma; GA101/RG7159, the first glyco-engineered humanized anti-CD20 monoclonal antibody for chronic lymphocytic leukemia and non-Hodgkins lymphoma; RG3616, a Hedgehog pathway inhibitor for the treatment of advanced basal ...

  • Roche uniquely positioned to deli... (18 Mar 2010 14:31)

    ... the treatment of malignant melanoma; GA101/RG7159, the first glyco-engineered humanized anti-CD20 monoclonal antibody for chronic lymphocytic leukemia and non-Hodgkin’s lymphoma; RG3616, a Hedgehog pathway inhibitor for the treatment of advanced basal ...

  • A prescription for life or death? (17 Mar 2010 23:25)

    ... until I am convincingly cured of my own medical problem, an aggressive form of chronic lymphocytic leukemia (CLL). I must happily stay in California, my adopted and beloved home for the ...

  • CytRx Reports 2009 Fourth Quarter Financial Results (15 Mar 2010 12:51)

    ... trials to evaluate the efficacy and safety of bafetinib in patients with high-risk B-cell chronic lymphocytic leukemia (B-CLL) and as a treatment for glioblastoma multiforme, a common and aggressive type of ...

  • Spot-on flea/tick meds may offer hope for mange (14 Mar 2010 05:53)

    ... male cat I adopted about 10 years ago. He has recently been diagnosed with chronic lymphocytic leukemia, which was found through routine blood work and which I am told is rare. ...

  • Micromet Gears for Pivotal Trial Raising $70M in Stock Offering (13 Mar 2010 03:18)

    ... acute lymphoblastic leukemia (ALL), and a Phase II trial of blinatumomab in patients with chronic lymphocytic leukemia. Micromet has reported promising Phase II results of the BiTE antibody in a Phase ...

  • Abbott Buys Facet to Strengthen Biologics Capabilities, Pharma Pipeline (14 Mar 2010 13:24)

    ... includes early- and mid-stage compounds for various types of cancer, including multiple myeloma and chronic lymphocytic leukemia. Daclizumab, Facet's lead product candidate, has big potential. For starters, Biogen will owe Facet ...

  • Memory Miles (15 Mar 2010 06:01)

    ... honored the memory of Officer Richard Dennison, who died in September 2008 after battling chronic lymphocytic leukemia for eight years, said Officer Lorenzo J. Uribe. "I've run marathons before ... and ...

  • Abbott's Acquisition Spree (10 Mar 2010 19:14)

    ... pipeline that are being developed for different types of cancer, including multiple myeloma and chronic lymphocytic leukemia. Under the terms of the definitive agreement between the companies, Abbott will commence a ...

  • Abbott to buy Facet (11 Mar 2010 04:30)

    ... developed with other parties. These compounds are targeting various cancers, including multiple myeloma and chronic lymphocytic leukemia, and Abbott believes they compliment its existing pipeline. ...

  • Facet Biotech Wooed by $722M Acquisition Offer from Abbott (11 Mar 2010 11:22)

    ... Additionally, the biotech owns half of the rights to Trubion Pharmaceuticals Inc.'s Phase I chronic lymphocytic leukemia drug TRU-016, as well as other CD37-directed protein therapeutics. ...

  • Abbott to buy Facet Biotech for $722M (11 Mar 2010 20:43)

    ... that are being studied to treat different types of cancer, including multiple myeloma and chronic lymphocytic leukemia. The transaction is expected to close in the second quarter of 2010. that concluded ...

  • Oncology: miR-31: A Small RNA That Promotes Lung Cancer (9 Mar 2010 06:04)

    ... microRNA (miRNA) molecules help control the oncogene responsible for a dangerous form of B-cell chronic lymphocytic leukemia (B-CLL), the ... > ...

  • Abbot to buy Facet Biotech for $450M (9 Mar 2010 22:16)

    ... that are being studied to treat different types of cancer, including multiple myeloma and chronic lymphocytic leukemia. The transaction is expected to close in the second quarter of 2010. ...

  • Abbott Enhances Pharmaceutical Pipeline with Acquisition of Facet Biotech / Provides Promising Biologic Intended to Treat Multiple Sclerosis and Compounds that Complement Abbott's Existing Diverse Oncology Program (9 Mar 2010 22:16)

    ... that are being studied to treat different types of cancer, including multiple myeloma and chronic lymphocytic leukemia. These novel compounds in development complement Abbott's leading-edge research in oncology, which includes three ...

see more newsletters

1-15/64 next next
image ad

Presswire

Press Release Distribution Service

see all press releases »

News publications

see all publications »